Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin

Biomaterials

Volumn 32, Issue 1, 2011, Pages 152-161

  Sarfati, Gadi ^a   Dvir, Tal ^a   Elkabets, Moshe ^a   Apte, Ron N ^a   Cohen, Smadar ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Laminin; Metastasis; Nanoparticles; Targeting

Indexed keywords

B16 MELANOMA; CARBOXYLIC GROUP; CHEMOTHERAPEUTIC DRUGS; EFFECTIVE THERAPY; FLOW CONDITION; IN-VITRO; LAMININ; LIGAND BINDING; LUNG CELLS; LUNG METASTASIS; MELANOMA METASTASIS; METASTASIS; METASTATIC CANCERS; METASTATIC LUNG CANCER; POLYMERIC NANOPARTICLES; RECEPTOR BINDING; TARGET SITES; TARGETING;

BIOLOGICAL ORGANS; DERMATOLOGY; DRUG THERAPY; MONOLAYERS; NANOPARTICLES; ONCOLOGY; PATHOLOGY; PEPTIDES; TUMORS;

CELL CULTURE;

LAMININ; LAMININ RECEPTOR; LAMININ RECEPTOR BINDING PEPTIDE; NANOPARTICLE; TYROSYLISOLEUCYLGLYCYLSERYLARGININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE; FOURIER TRANSFORMATION; INFRARED SPECTROSCOPY; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAVENOUS; LAMININ; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROFLUIDICS; NANOPARTICLES; OLIGOPEPTIDES; POLYMERS; RHEOLOGY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; TISSUE DISTRIBUTION;

MUS;

EID: 78349308005     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.014     Document Type: Article

References (31)

1. Gu J., Cheng W.P., Liu J., Lo S.Y., Smith D., Qu X., et al. pH-triggered reversible ″ stealth″ polycationic micelles. Biomacromolecules 2008, 9:255-262.
2. Gao Z.G., Lee D.H., Kim D.I., Bae Y.H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. J Drug Target 2005, 13:391-397.
3. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
4. Bagalkot V., Farokhzad O.C., Langer R., Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006, 45:8149-8152.
5. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315-6320.
6. Liotta L.A. Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. Am J Pathol 1984, 117:339-348.
7. Magnifico A., Tagliabue E., Buto S., Ardini E., Castronovo V., Colnaghi M.I., et al. Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. J Biol Chem 1996, 271:31179-31184.
8. Vacca A., Ribatti D., Roncali L., Lospalluti M., Serio G., Carrel S., et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993, 72:455-461.
9. Graf J., Ogle R.C., Robey F.A., Sasaki M., Martin G.R., Yamada Y., et al. A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor. Biochemistry 1987, 26:6896-6900.
10. Segal E., Pan H., Ofek P., Udagawa T., Kopeckova P., Kopecek J., et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009, 4:e5233.
11. Dong Q.G., Bernasconi S., Lostaglio S., De Calmanovici R.W., Martin-Padura I., Breviario F., et al. A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 1997, 17:1599-1604.
12. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
13. Hart I.R., Fidler I.J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40:2281-2287.
14. Spectrometric identification of organic compounds 1991, John Wiley & Sons. 5th ed. B. Silverstein, Morrill (Eds.).
15. Yoshida N., Ishii E., Nomizu M., Yamada Y., Mohri S., Kinukawa N., et al. The laminin-derived peptide YIGSR (Tyr-Ile-Gly-Ser-Arg) inhibits human pre-B leukaemic cell growth and dissemination to organs in SCID mice. Br J Cancer 1999, 80:1898-1904.
16. McAbee D.D., Grinnell F. Fibronectin-mediated binding and phagocytosis of polystyrene latex beads by baby hamster kidney cells. J Cell Biol 1983, 97:1515-1523.
17. Seib F.P., Jones A.T., Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release 2007, 117:291-300.
18. Sakamoto N., Iwahana M., Tanaka N.G., Osada Y. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res 1991, 51:903-906.
19. Martin G.R., Timpl R. Laminin and other basement membrane components. Annu Rev Cell Biol 1987, 3:57-85.
20. Graf J., Iwamoto Y., Sasaki M., Martin G.R., Kleinman H.K., Robey F.A., et al. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987, 48:989-996.
21. Chambers B.J., Klein N.W., Conrad S.H., Ruppenthal G.C., Sackett G.P., Weeks B.S., et al. Reproduction and sera embryotoxicity after immunization of monkeys with the laminin peptides YIGSR, RGD, and IKVAV. Proc Natl Acad Sci U S A 1995, 92:6818-6822.
22. Tomiyama Y., Tsubakio T., Piotrowicz R.S., Kurata Y., Loftus J.C., Kunicki T.J. The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules. Blood 1992, 79:2303-2312.
23. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238:491-497.
24. Iwamoto Y., Robey F.A., Graf J., Sasaki M., Kleinman H.K., Yamada Y., et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987, 238:1132-1134.
25. Belhocine T.Z., Scott A.M., Even-Sapir E., Urbain J.L., Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006, 47:957-967.
26. Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 2001, 28:2-7.
27. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000, 7:53-62.
28. Vidal-Vanaclocha F., Amezaga C., Asumendi A., Kaplanski G., Dinarello C.A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994, 54:2667-2672.
29. Minow R.A., Benjamin R.S., Lee E.T., Gottlieb J.A. Adriamycin cardiomyopathy-risk factors. Cancer 1977, 39:1397-1402.
30. Bristow M.R., Billingham M.E., Mason J.W., Daniels J.R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978, 62:873-879.
31. Field K.M., Dow C., Michael M. Part I: liver function in oncology: biochemistry and beyond. Lancet Oncol 2008, 9:1092-1101.